Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Observatory
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Signals Session
  • Bespoke Projects
  • Use Cases
  • Readinessfree
  • Signals
  • Free scan↗free
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
solutions
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Partners
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
ResearchServicesSignalsAbout
ResearchServicesSignalsAbout
  1. Home
  2. Research
  3. Helix
  4. mRNA Therapeutic Platform Expansion

mRNA Therapeutic Platform Expansion

Moderna and BioNTech are expanding mRNA technology beyond COVID vaccines to cancer immunotherapy, rare genetic diseases, autoimmune disorders, and combination flu-COVID vaccines entering market in 2026.

Geography: Americas · North America · United States

Back to HelixBack to United StatesView interactive version

The mRNA platform validated by COVID vaccines is being applied to a much broader range of therapeutic applications. Moderna has over 40 programs in its pipeline including personalized cancer vaccines (mRNA-4157/V940 in Phase III with Merck), rare disease treatments, and combination respiratory vaccines. BioNTech's individualized neoantigen therapy uses mRNA to train each patient's immune system against their specific tumor mutations.

mRNA's advantage is speed and flexibility: once the platform is proven, designing a new mRNA therapeutic is primarily a software problem — change the sequence, test manufacturing, and go. This enables personalized medicine at scale and rapid response to emerging threats. Combination flu-COVID vaccines are expected to reach market in 2026, simplifying annual vaccination.

The US maintains leadership in mRNA technology through Moderna (Cambridge, MA) and its academic ecosystem. The technology has implications beyond medicine: mRNA-based agriculture (pest-resistant crops without permanent genetic modification), veterinary medicine, and industrial biotechnology are emerging applications. The platform's ability to be rapidly adapted makes it a strategic capability for pandemic preparedness and biodefense.

TRL
7/9Operational
Impact
5/5
Investment
4/5
Category
Applications

Research this in Signals

Scan mRNA Therapeutic Platform Expansion for yourself.

Signals turns a topic into a sourced research record you can inspect and rerun. Your first scan is free, and this one starts with mRNA Therapeutic Platform Expansion already loaded, so edit it or scan as is.